A Phase 1 interventional study of anle138b (TEV-56286) and Fluvoxamine 100 mg QD for 5 days in Healthy Volunteers, sponsored by MODAG GmbH. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-23.
Sponsored by MODAG GmbH · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Multiple System Atrophy with a site in United Kingdom — 4 open to participants now, 5 under way, 1 of them phase 3. Multiple System Atrophy · United Kingdom.
Among the 19 studies in Multiple System Atrophy with a site in United Kingdom, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2022, is one of 4 in phase 1, and was the 16th registered.
207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.
Browse Multiple System Atrophy studies →4 of the 19 studies in Multiple System Atrophy with a site in United Kingdom are open now. Recruiting first, the newest first:
Queen Mary University of London · Sites in United Kingdom
Ages 18+
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Ionis Pharmaceuticals, Inc. · Sites in United Kingdom, Austria, France and 2 more countries
Ages 40–70
University of Exeter · Sites in United Kingdom
Ages 45–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is above the median of 41 across 134 interventional studies indexed under Multiple System Atrophy.
Median enrollment 74 across the 16 interventional studies, 198 across the 3 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 19 have an industry lead sponsor. The 10 most frequent:
MODAG GmbH is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
MODAG GmbH has 5 studies filed under Multiple System Atrophy — fewer than ten, so there is no comparison to draw.
2 of the studies in Multiple System Atrophy with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05121012University of ExeterSynaptic Loss in Multiple System Atrophy | 2027-03-31 |
| NCT04165486Ionis Pharmaceuticals, Inc.Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Multiple System Atrophy with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this healthy volunteers drug-drug interaction study is to assess the CYP1A2 and CYP3A4 perpetrator interaction potential and CYP1A2 victim potential of TEV-56286 (anle138b).
This a 2-part DDI study that will assess the CYP1A2 and CYP3A4 perpetrator interaction potential of TEV-56286 single dose and multiple dose, using caffeine and midazolam as substrates and CYP1A2 victim potential of TEV-56286 (anle138b) at steady state induction using fluvoxamine as inhibitor [1,2].The estimated time from screening until the follow-up visit is approximately up to 8 weeks for each subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TEV-56286 300 mg QD (single dose and multiple dose for 14 days) Victim drugs: Caffeine 200 mg Midazolam 2 mg
Drug: anle138b (TEV-56286)
Drug: fluvoxamine 100 mg QD for 5 days Victim drug: TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine
Drug: Fluvoxamine 100 mg QD for 5 days
Anle138b (TEV-56286) as perpetrator
Also known as: Caffeine, Midazolam, Fluvoxamine
Anle138b (TEV-56286) as victim
Also known as: TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine
Oral pharmacokinetics (PK) of caffeine administered without TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: Cmax for caffeine.
Time frame: Day 1
Oral pharmacokinetics (PK) of caffeine administered without TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC(0-inf) for caffeine.
Time frame: Day 1
Oral pharmacokinetics (PK) of caffeine administered without TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC (0-last) for caffeine.
Time frame: Day 1
Oral pharmacokinetics (PK) of midazolam administered without TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: Cmax for midazolam.
Time frame: Day 1
Oral pharmacokinetics (PK) of midazolam administered without TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC(0-inf) for midazolam.
Time frame: Day 1
Oral pharmacokinetics (PK) of midazolam administered without TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC (0-last) for midazolam.
Time frame: Day 1
Oral pharmacokinetics (PK) of caffeine after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).
Cmax for caffeine.
Time frame: Day 3
Oral pharmacokinetics (PK) of caffeine after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC(0-inf) for caffeine.
Time frame: Day 3
Oral pharmacokinetics (PK) of caffeine after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC (0-last) for caffeine.
Time frame: Day 3
Oral pharmacokinetics (PK) of midazolam after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).
Cmax for midazolam
Time frame: Day 3
Oral pharmacokinetics (PK) of midazolam after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC(0-inf) for midazolam.
Time frame: Day 3
Oral pharmacokinetics (PK) of midazolam after single co-administration with TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC (0-last) for midazolam.
Time frame: Day 3
Oral pharmacokinetics (PK) of caffeine after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: Cmax for caffeine.
Time frame: Day 18
Oral pharmacokinetics (PK) of caffeine after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).
AUC(0-inf) for caffeine.
Time frame: Day 18
Oral pharmacokinetics (PK) of caffeine after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC (0-last) for caffeine.
Time frame: Day 18
Oral pharmacokinetics (PK) of midazolam after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: Cmax for midazolam.
Time frame: Day 18
Oral pharmacokinetics (PK) of midazolam after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC(0-inf) for midazolam.
Time frame: Day 18
Oral pharmacokinetics (PK) of midazolam after repeated administration of TEV-56286 in healthy volunteers in the fasted state (Part I).
PK parameter: AUC (0-last) for midazolam.
Time frame: Day 18
Oral pharmacokinetics (PK) of TEV-56286 without fluvoxamine in healthy volunteers after repeated administration in the fasted state (Part II).
PK parameter: Cmax for TEV-56286.
Time frame: Day 14
Oral pharmacokinetics (PK) of TEV-56286 without fluvoxamine in healthy volunteers after repeated administration in the fasted state (Part II).
PK parameter: AUC(0-tau) for TEV-56286.
Time frame: Day 14
Oral pharmacokinetics (PK) of TEV-56286 in healthy volunteers after repeated co-administration with fluvoxamine in the fasted state.
PK parameter: Cmax for TEV-56286 (Part II).
Time frame: Day 19
Oral pharmacokinetics (PK) of TEV-56286 in healthy volunteers after repeated co-administration with fluvoxamine in the fasted state.
PK parameter: AUC(0-tau) for TEV-56286 (Part II).
Time frame: Day 19
Oral pharmacokinetics (PK) of substrates caffeine and midazolam
PK parameter: Tmax
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of substrates caffeine and midazolam
PK parameter: Tlag
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of substrates caffeine and midazolam
PK parameter: lambda-z
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of substrates caffeine and midazolam
PK parameter: T1/2
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of substrates caffeine and midazolam
PK parameter: CL/F
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of substrates caffeine and midazolam
PK parameter: Vz/F
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine
PK parameter: Tmax
Time frame: Day 19
Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine
PK parameter: lambda-z
Time frame: Day 19
Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine
PK parameter: T1/2
Time frame: Day 19
Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine
PK parameter: CL/F
Time frame: Day 19
Oral pharmacokinetics (PK) of TEV-56286 after repeated co-administration with fluvoxamine
PK parameter: Vz/F
Time frame: Day 19
Oral pharmacokinetics (PK) of TEV-56286 as perpetrator drug after co-administration with caffeine and midazolam
PK parameter: Tmax
Time frame: Day 3
Oral pharmacokinetics (PK) of TEV-56286 as perpetrator drug after co-administration with caffeine and midazolam
PK parameter: Cmax
Time frame: Day 3
Oral pharmacokinetics (PK) of TEV-56286 as perpetrator drug after co-administration with caffeine and midazolam
PK parameter: AUC (0-last)
Time frame: Day 3
Oral pharmacokinetics (PK) of TEV-56286
PK parameter: Trough concentration for TEV-56286
Time frame: Day 3-18
Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam
PK parameter: Tmax
Time frame: Day 18
Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam
PK parameter: Cmax
Time frame: Day 18
Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam
PK parameter: Cmin
Time frame: Day 18
Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam
PK parameter: Cavg
Time frame: Day 18
Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam
PK parameter: AUC (0-tau)
Time frame: Day 18
Oral pharmacokinetics (PK) of TEV-56286 after single co-administration with caffeine and midazolam
PK parameter: AUC (0-last)
Time frame: Day 18
Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286
PK parameter: Tmax
Time frame: Day 19
Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286
PK parameter: Cmax
Time frame: Day 19
Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286
PK parameter: Cmin
Time frame: Day 19
Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286
PK parameter: Cavg
Time frame: Day 19
Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286
PK parameter: AUC (0-tau)
Time frame: Day 19
Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286
PK parameter: AUC (0-last)
Time frame: Day 19
Oral pharmacokinetics (PK) of fluvoxamine after repeated co-administration with TEV-56286
PK parameter: Trough concentration for fluvoxamine
Time frame: Day 15-19
Oral pharmacokinetics (PK) of TEV-56286 after first dose administered as part of repeated administration
PK parameter: Tlag for TEV-56286
Time frame: Day 1
Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose
PK parameter: Tmax
Time frame: Day 1, Day 14
Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose
PK parameter: Cmax
Time frame: Day 1, Day 14
Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose
PK parameter: AUC (0-tau)
Time frame: Day 1, Day 14
Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose
PK parameter: lambda-z
Time frame: Day 1, Day 14
Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose
PK parameter: T1/2
Time frame: Day 1, Day 14
Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose
PK parameter: CL/F
Time frame: Day 1, Day 14
Oral pharmacokinetics (PK) of TEV-56286 following single dose and multiple dose
PK parameter: Vz/F
Time frame: Day 1, Day 14
Oral pharmacokinetics (PK) of TEV-56286 following multiple dose
PK parameter: AUC (0-last)
Time frame: Day 14
Oral pharmacokinetics (PK) of TEV-56286 following multiple dose
PK parameter: Cmin
Time frame: Day 14
Oral pharmacokinetics (PK) of TEV-56286 following multiple dose
PK parameter: Cavg
Time frame: Day 14
Oral pharmacokinetics (PK) of TEV-56286 following multiple dose
PK parameter: Accumulation ratio
Time frame: Day 14
Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam
PK parameter: Tmax
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam
PK parameter: Cmax
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam
PK parameter: AUC (0-last)
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam
PK parameter: AUC (0-inf)
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam
PK parameter: lambda-z
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam
PK parameter: T1/2
Time frame: Day 1, Day 3, Day 18
Oral pharmacokinetics (PK) of metabolites paraxanthine and 1-hydroxy midazolam after single administration of caffeine and midazolam
PK parameter: parent: metabolite ratio
Time frame: Day 1, Day 3, Day 18
Incidence of treatment-emergent adverse events including clinically significant changes in vital signs, ECGs and safety labs
adverse events and clinically significant changes in vital signs, ECGs and safety labs
Time frame: Day 1 up to follow up visit (5-11 days post last TEV-56286 dose)
Number of participants reporting use of concomitant medications
Number of participants reporting use of concomitant medications
Time frame: Day 1 up to follow up visit (5-11 days post last TEV-56286 dose)
Columbia-Suicide Severity Rating Scale (C-SSRS) total score
Columbia-Suicide Severity Rating Scale (C-SSRS) total score
Time frame: Day 3 to day 21
Plan to share: No
Ran from Sep 2022 to primary completion in Jan 2023, 4 months.
Of 25 phase 1 interventional studies under Multiple System Atrophy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 55. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Emrusolmin · Fluvoxamine